中国循证心血管医学杂志

[1] Toyama T,Neuen BL,Jun M,et al. Effect of SGLT2 inhibitors on cardiovascular,renal and safety outcomes in patients with type 2diabetes mellitus and chronic kidney disease:A systematic review and meta-analysis[J]. Diabetes Obes Metab,2019,21(5):1237-50.

[2] Elrakaybi A,Laubner K,Zhou Q,et al. Cardiovascular protection by SGLT2 inhibitors-Do anti-inflammatory mechanisms play a role?[J].Mol Metab,2022,64:101549.

[3] La Grotta R,De Candia P,Olivieri F,et al. Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin[J]. Cell Mol Life Sci,2022,79(5):273.

[4] Theofilis P,Sagris M,Oikonomou E,et al. The impact of SGLT2inhibitors on inflammation:A systematic review and meta-analysis of studies in rodents[J]. Int Immunopharmacol,2022,111:109080.

[5] Gohari S,Reshadmanesh T,Khodabandehloo H,et al. The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease:the EMPA-CARD randomized controlled trial[J]. Diabetol Metab Syndr,2022,14(1):170.

[6] Ejiri K,Miyoshi T,Kihara H,et al. Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure[J]. Sci Rep,2022,12(1):15449.

[7] Liberati A,Altman DG,Tetzlaff J,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions:explanation and elaboration[J].BMJ,2009,339:b2700.

[8] Cumpston M,Li T,Page MJ,et al. Updated guidance for trusted systematic reviews:a new edition of the Cochrane Handbook for Systematic Reviews of Interventions[J]. Cochrane Database Syst Rev,2019,10(10):ED142.

[9] Benedikt M,Mangge H,Aziz F,et al. Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction–a post-hoc analysis of the EMMY trial[J]. Cardiovascular Diabetology,2023,22(1):166.

[10] Omar M,Jensen J,Kistorp C,et al. The effect of empagliflozin on growth differentiation factor 15 in patients with heart failure:a randomized controlled trial(Empire HF Biomarker)[J]. Cardiovascular Diabetology,2022,21(1):34.

[11] Oldgren J,Laurila S,?kerblom A,et al. Effects of 6 weeks of treatment with dapagliflozin,a sodium-glucose co-transporter-2inhibitor,on myocardial function and metabolism in patients with type2 diabetes:A randomized,placebo-controlled,exploratory study[J].Diabetes,Obesity and Metabolism,2021,23(7):1505-17.

[12] Cheng L,Fu Q,Zhou L,et al. Dapagliflozin,metformin,mono therapy or both in patients with metabolic syndrome[J]. Sci Rep,2021,11(1):24263.

[13] Katakami N,Mita T,Yoshii H,et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2diabetes:A prospective,randomized,open-label,parallel-group comparative study[J]. Cardiovascular Diabetology,2020,19(1):110.

[14] Phrommintikul A,Wongcharoen W,Kumfu S,et al. Effects of dapagliflozin vs vildagliptin on cardiometabolic parameters in diabetic patients with coronary artery disease:a randomised study[J].British Journal of Clinical Pharmacology,2019,85(6):1337-47.

[15] Hattori S. Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance[J]. Diabetol Metab Syndr,2018,10:93.

[16] Ishihara H,Yamaguchi S,Nakao I,et al. Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus(IOLITE):a multicentre,randomized,placebo-controlled,double-blind study[J].Diabetes,Obesity and Metabolism,2016,18(12):1207-16.

[17] Sato T,Aizawa Y,Yuasa S,et al. The effect of dapagliflozin treatment on epicardial adipose tissue volume[J]. Cardiovasc Diabetol,2018,17(1):6.

[18] Kinoshita T,Shimoda M,Nakashima K,et al. Comparison of the effects of three kinds of glucose-lowering drugs on nonalcoholic fatty liver disease in patients with type 2 diabetes:A randomized,open-label,three-arm,active control study[J]. J Diabetes Investig,2020,11(6):1612-22.

[19] Phrueksotsai S,Pinyopornpanish K,Euathrongchit J,et al. The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol,2021,36(10):2952-9.

[20] Sakurai S,Jojima T,Iijima T,et al. Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1(PAI-1)in patients with type 2 diabetes:Association with improvement of fibrinolysis[J]. J Diabetes Complications,2020,34(11):107703.

[21] Ito D,Shimizu S,Inoue K,et al. Comparison of Ipragliflozin and Pioglitazone effects on Nonalcoholic fatty liver disease in patients with type 2 diabetes:A randomized,24-week,open-label,activecontrolled trial[J]. Diabetes Care,2017,40(10):1364-72.

[22] Shigiyama F,Kumashiro N,Miyagi M,et al. Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus:DEFENCE study[J]. Cardiovascular Diabetology,2017,16(1):84.

[23] Bailey CJ,Iqbal N,T'Joen C,et al. Dapagliflozin monotherapy in drugnaive patients with diabetes:a randomized-controlled trial of lowdose range[J]. Diabetes Obes Metab,2012,14(10):951-9.

[24] Latva-Rasku A,Honka M J,Kullberg J,et al. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity:A Randomized,Double-Blind,Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients[J]. Diabetes Care,2019,42(5):931-7.

[25] Shi M,Zhang H,Wang W,et al. Effect of dapagliflozin on liver and pancreatic fat in patients with type 2 diabetes and non-alcoholic fatty liver disease[J]. Journal of Diabetes and its Complicatio ns,2023,37(10):108610.

[26] Ge T,Yang Y,Zhao Y. A study of the efficacy of sacubitril/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease[J]. Perfusion(United Kingdom),2023,38(8):1697-704.

[27] Antlanger M,Domenig O,Kaltenecker CC,et al. Combined sodium glucose co-transporter-2 inhibitor and angiotensin-converting enzyme inhibition upregulates the renin-angiotensin system in chronic kidney disease with type 2 diabetes:Results of a randomized,double-blind,placebo-controlled exploratory trial[J].Diabetes,Obesity and Metabolism,2022,24(5):816-26.

[28] Nomura S,Shouzu A,Taniura T,et al. Effects of Tofogliflozin and Anagliptin Alone or in Combination on Glucose Metabolism and Atherosclerosis-Related Markers in Patients with Type2 Diabetes Mellitus[J]. Clinical Pharmacology:Advances and Applications,2023,15:41-55.

[29] Eriksson JW,Lundkvist P,Jansson PA,et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes:a double-blind randomised placebocontrolled study[J]. Diabetologia,2018,61(9):1923-34.

[30] O i k o n o m o u E K, A n t o n i a d e s C. T h e r o l e o f a d i p o s e tissue in cardiovascular health and disease[J]. Nat Rev Cardiol,2019,16(2):83-99.

[31] Bray J,Foster-Davies H,Stephens JW. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors(SGLT2is)on biomarkers of inflammation and oxidative stress[J]. Diabetes Res Clin Pract,2020,168:108368.

[32] Xu L,Nagata N,Chen G,et al. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet[J]. BMJ Open Diabetes Res Care,2019,7(1):e783.

[33] Zhao S,Kusminski CM,Scherer PE. Adiponectin,Leptin and Cardiovascular Disorders[J]. Circ Res,2021,128(1):136-49.

[34] Wu P,Wen W,Li J,et al. Systematic Review and Meta-Analysis of Randomized Controlled Trials on the Effect of SGLT2 Inhibitor on Blood Leptin and Adiponectin Level in Patients with Type 2Diabetes[J]. Horm Metab Res,2019,51(8):487-94.

[35] Faridvand Y,Kazemzadeh H,Vahedian V,et al. Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK/SIRT1 activation[J]. Clin Exp Pharmacol Physiol,2022,49(6):643-51.

[36] Packer M. Critical examination of mechanisms underlying the reduction in heart failure events with SGLT2 inhibitors:identification of a molecular link between their actions to stimulate erythrocytosis and to alleviate cellular stress[J]. Cardiovasc Res,2021,117(1):74-84.

[37]董亚兰,胡德胜.动脉粥样硬化的炎症应答特征及运用[J].中国动脉硬化杂志,2022,30(4):304-12.

[38] Khunti K,Kosiborod M,Kim DJ,et al. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents:analysis of CVD-REAL data[J]. Cardiovasc Diabetol,2021,20(1):159.